110480-86-9

Basic information

• Product Name: (1S)-1-Amino-2-methyl-1-phenylpropan-2-ol
• Synonyms: (1S)-1-Amino-2-methyl-1-phenylpropan-2-ol;(S)-1-aMino-2-Methyl-1-phenylpropan-2-ol;1-Amino-2-methyl-1-phenylpropan-2-ol hydrochloride
• CAS NO: 110480-86-9
• Molecular Formula: C₁₀H₁₅NO
• Molecular Weight: 165.234
• Mol File: 110480-86-9.mol

Chemical Properties

• Melting Point: 47-50℃
• Boiling Point: 295 °C at 760 mmHg
• Flash Point: 132.2 °C
• Appearance: /
• Density: 1.050
• PKA: 12.65±0.50(Predicted)
• CAS DataBase Reference: (1S)-1-Amino-2-methyl-1-phenylpropan-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: (1S)-1-Amino-2-methyl-1-phenylpropan-2-ol(110480-86-9)
• EPA Substance Registry System: (1S)-1-Amino-2-methyl-1-phenylpropan-2-ol(110480-86-9)

Safety Data

• Hazardous Substances Data: 110480-86-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(1S)-1-Amino-2-methyl-1-phenylpropan-2-ol is used as a reactant/reagent for the stereoselective preparation of diaryl carbonyl compounds. This is achieved through palladium-catalyzed enantioselective redox-relay oxidative Heck arylation of arylboronic acids and homoallylic alcohols. The resulting diaryl carbonyl compounds are valuable intermediates in the synthesis of pharmaceuticals, agrochemicals, and other bioactive molecules, where the stereochemistry of the starting material can significantly influence the biological activity of the final product.
Used in Chemical Research:
In the field of chemical research, (1S)-1-Amino-2-methyl-1-phenylpropan-2-ol serves as a valuable building block for the development of new synthetic methodologies and the exploration of novel reaction mechanisms. Its unique structure and reactivity make it an attractive candidate for studying asymmetric catalysis, enantioselective reactions, and the development of new chiral ligands or catalysts.
Used in Material Science:
(1S)-1-Amino-2-methyl-1-phenylpropan-2-ol can also be utilized in the synthesis of chiral materials, such as polymers, liquid crystals, and other functional materials. The incorporation of this chiral amine into the structure of these materials can lead to unique properties, such as enhanced selectivity, improved performance, or novel applications in various industries, including electronics, sensors, and coatings.

InChI:InChI=1S/C10H15NO/c1-10(2,12)9(11)8-6-4-3-5-7-8/h3-7,9,12H,11H2,1-2H3/t9-/m0/s1

Upstream product

• 2935-35-5 (S)-2-phenylglycine 
• 145513-97-9 (S)-(+)-2-phenyl-N-(trifluoroacetyl)glycine methyl ester 
• 143978-88-5 N-tert-butoxycarbonyl-L-phenylglycine methyl ester 
• 6591-61-3 (S)-Phenylglycine methyl ester 
• 15028-39-4 L-2-phenylglycine methyl ester hydrochloride 
• 74-88-4 methyl iodide 
• 723263-00-1 (S)-(2-hydroxy-2-methyl-1-phenylpropyl)carbamic acid tert-butyl ester 
• 145439-97-0 (S)-2,2,2-trifluoro-N-[2-hydroxy-2-methyl-1-phenylpropyl]acetamide 
• 13226-98-7 methyl (S)-2-amino-2-phenylacetate hydrochloride 
• 75-16-1 methylmagnesium bromide 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 145439-95-8 N,N'-Bis-((S)-2-hydroxy-2-methyl-1-phenyl-propyl)-2,2-dimethyl-malonamide 
• 639057-74-2 bis((S)-5,5-dimethyl-4-phenyl-4,5-dihydrooxazol-2-yl)methane 
• 144899-42-3 (4S)-2,2,5,5-tetramethyl-4-phenylmethyloxazolidine 
• 168297-84-5 (4S)-5,5-dimethyl-4-phenyl-1,3-oxazolidin-2-one 
• 1310478-00-2 (1r,4r)-N-((S)-2-hydroxy-2-methyl-1-phenylpropyl)-1-methyl-4-(4-(trifluoromethyl)phenylsulfonamido)cyclohexanecarboxamide 
• 145439-96-9 C₂₅H₃₀N₂O₂ 
• 723263-80-7 (S)-(2-benzyloxy-3,5-dimethoxy-4-methylphenyl)-[(1S)-2-hydroxy-2-methyl-1-phenylpropylamino]acetic acid benzyl ester 
• 723263-98-7 N-{4-[(S)-benzylcarbamoyl-(S-2-hydroxy-2-methyl-1-phenylpropylamino)methyl]phenyl}benzamide 
• 723263-77-2 (S)-(2-hydroxy-3,5-dimethoxy-4-methylphenyl)-[(1S)-2-hydroxy-2-methyl-1-phenylpropylamino]acetic acid benzyl ester 
• 723264-01-5 N-{4-[(S)-benzylcarbamoyl(benzylideneamino)methyl]phenyl}benzamide 
• 723263-25-0 (3S,5S)-3-(5-hydroxy-2,4-dimethoxy-3-methylphenyl)-6,6-dimethyl-5-phenylmorpholin-2-one 
• 723263-95-4 (3S,5S)-3-[4-(benzoylamino)phenyl]-6,6-dimethyl-5-phenylmorpholin-2-one 
• 723263-58-9 (3S,5S)-3-(4-benzyloxyphenyl)-6,6-dimethyl-5-phenylmorpholin-2-one 

Relevant articles and documents

Enantioselective Synthesis of N-Benzylic Heterocycles: A Nickel and Photoredox Dual Catalysis Approach

Reported herein is a dual nickel- and photoredox-catalyzed modular approach for the preparation of enantioenriched N-benzylic heterocycles. α-Heterocyclic carboxylic acids, easily obtainable from common commercial material, are reported as suitable substrates for a decarboxylative strategy in conjunction with a chiral pyridine-oxazoline (PyOx) ligand, providing quick access to enantioenriched drug-like products. The presence of a directing group on the heterocyclic moiety is shown to be beneficial, affording improved stereoselectivity in a number of cases.

Catalytic Asymmetric Intermolecular Cyclopropanation of a Ketone Carbene Precursor by a Ruthenium(II)-Pheox Complex

The diazo derivative of acetonyl acetate is a useful basic skeleton for the synthesis of cyclopropyl ketones. The intermolecular cyclopropanations of diazo acetoxy acetone with olefins are accomplished by using a novel p-nitro-Ru(II)-diphenyl-Pheox catalyst to give the corresponding optically active cyclopropane derivatives in good yields (up to 95%) with excellent diastereoselectivities (up to 99:1) and enantioselectivities (up to 98% ee). (Figure presented.).

SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES

The invention relates to substituted dihydropyrazolo pyrazine carboxamide derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and diabetes, and also urogenital and ophthalmic disorders.

ERK INHIBITORS

Disclosed are the ERK inhibitors of formula (1.0) and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1.0). This invention provides compounds that are ERK inhibitors (i.e., ERK2 inhibitors). This invention also provides a pharmaceutical composition comprising an effective amount of at least one (e.g., 1) compound of formula (1.0) and a pharmaceutically acceptable carrier.

N -heteropolycyclic compounds from the formal intramolecular (4 + 1)-cycloaddition of chromium aminocarbenes

Chromium aminocarbenes tethered to dienes of all three electronic natures undergo an efficient intramolecular (4 + 1)-cycloaddition to give N-heteropolycyclic compounds. Ligands on chromium had a profound effect on the course of the reaction.

BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF

The present invention provides compounds of formula (I); or pharmaceutically acceptable salts thereof, wherein the variables are defined as herein. The present invention provides a method for manufacturing the compounds of formula (I), their therapeutic u

HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS

The invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, thereof, wherein: G is a group of formula (II); and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates, thereof, wherein A, B. L1-L4 A, B, R1-R4 and m are as defined herein. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and their use in treating a bacterial infection.

Substituted pteridines for the treatment of inflammatory diseases

The invention relates to new pteridines which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers, as

Ruthenium-catalyzed asymmetric epoxidation of olefins using H 2O2, part I: Synthesis of new chiral N,N,N,-tridentate pybox and pyboxazine ligands and their ruthenium complexes

The synthesis of chiral tridentate N,N,N-pyridine-2.6-bisoxazolines 3 (pyhox ligands) and N,N,N-pyridine-2.6-bisoxazines 4 (pyboxazine ligands) is described in detail. These novel ligands constitute a useful tool-box for the application in asymmetric catalysis. Compounds 3 and 4 are conveniently prepared by cyclization of enantiomerically pure α- or β-amino al cohols with dimethyl pyridine-2,6-dicarboximidate. The corresponding ruthenium complexes are efficient asymmetric epoxidation catalysts and have been prepared in good yield and fully char acterized by spectroscopic means. Four of these ruthenium complexes have been characterized by X-ray crystallography. For the first time the molecular structure of a pyboxazine complex (2,6-bis-[(4S)-4-phenyl-5,6- dihydro-4H-[1,3]oxazinyl]pyridine)(pyridine-2,6-dicarboxylate)ruthenium (S)-2aa, is presented.